Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the first clinical readout from ...

Discover Guardant Health's FDA breakthroughs & revenue growth! Learn why profitability-focused investors might hold back ...

Cathie Wood’s ARK ETFs have released their daily trade report for Tuesday, 22 July 2025, showcasing a series of strategic buy ...

Guardant abandons cancer blood test trial early, restates confidence in product line Guardant stopped enrolling new patients in the study because of its design and use of an older generation test, ...

Eiichiro Oda has a distinct style that's a mixture of goofy and intimidating, but that might not fit the reveal of the most anticipated character of One Piece.

PALO ALTO, Calif.-- (BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2025 after market ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2025 after market close on Wednesday, July 30, 2025.

If you haven’t heard of The Handmaid’s Tale by now, you’ve probably been living under a rock or maybe in your own personal Gilead.

New integration brings Guardant Health's complete oncology testing portfolio into the VieCure Halo Intelligence platform, streamlining access to precision diagnostics at the point of care DENVER ...

Guardant's precision oncology tests are now available to the hundreds of providers who rely on the Halo Intelligence platform for real-time oncology insights nationwide.